<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Prz Gastroenterol</journal-id><journal-id journal-id-type="iso-abbrev">Prz Gastroenterol</journal-id><journal-id journal-id-type="publisher-id">PG</journal-id><journal-title-group><journal-title>Przegl&#x00061;&#x0031c;d Gastroenterologiczny</journal-title></journal-title-group><issn pub-type="ppub">1895-5770</issn><issn pub-type="epub">1897-4317</issn><publisher><publisher-name>Termedia Publishing House</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26557940</article-id><article-id pub-id-type="pmc">4631277</article-id><article-id pub-id-type="publisher-id">24567</article-id><article-id pub-id-type="doi">10.5114/pg.2015.49001</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Paper</subject></subj-group></article-categories><title-group><article-title>Comparing the efficacy of four different protocols for eradicating of <italic>Helicobacter pylori</italic> infection in Ahvaz, southwest Iran</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Masjedizadeh</surname><given-names>Abdolrahim</given-names></name><xref ref-type="aff" rid="AF0001">1</xref></contrib><contrib contrib-type="author"><name><surname>Zaeemzadeh</surname><given-names>Narjes</given-names></name><xref ref-type="aff" rid="AF0002">2</xref></contrib><contrib contrib-type="author"><name><surname>Mard</surname><given-names>Seyyed Ali</given-names></name><xref ref-type="aff" rid="AF0001">1</xref></contrib><contrib contrib-type="author"><name><surname>Vanani</surname><given-names>Ghazal Salehi</given-names></name><xref ref-type="aff" rid="AF0001">1</xref></contrib></contrib-group><aff id="AF0001"><label>1</label>Research Center for Infectious Diseases of Digestive System, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran</aff><aff id="AF0002"><label>2</label>Research Center for Infectious Diseases of Digestive System, Departement of Pharmacology, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran</aff><author-notes><corresp id="cor1"><bold>Address for correspondence:</bold> Prof. Abdolrahim Masjedizadeh, Research Center for Infectious Diseases of Digestive System, Ahvaz Jundishapour University of Medical Sciences, Golestan, 6155837539 Ahvaz, Iran. phone: +989161114970, fax: +986113910642. e-mail: <email xlink:href="masjedi-r@ajums.ac.ir">masjedi-r@ajums.ac.ir</email></corresp></author-notes><pub-date pub-type="epub"><day>10</day><month>2</month><year>2015</year></pub-date><pub-date pub-type="ppub"><year>2015</year></pub-date><volume>10</volume><issue>2</issue><fpage>94</fpage><lpage>99</lpage><history><date date-type="received"><day>06</day><month>7</month><year>2014</year></date><date date-type="rev-recd"><day>21</day><month>9</month><year>2014</year></date><date date-type="accepted"><day>11</day><month>10</month><year>2014</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2015 Termedia</copyright-statement><copyright-year>2015</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-nd/3.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial 3.0 Unported License, permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec id="st1"><title>Introduction</title><p><italic>Helicobacter pylori</italic> (<italic>H. pylori</italic>) is the common cause of many gastrointestinal diseases, especially peptic ulcer. Therefore, a successful treatment of this infection decreases the financial burden on health systems.</p></sec><sec id="st2"><title>Aim</title><p>Different combinations of antibiotics are used for the eradication of this bacterium worldwide. The goal of this study is to compare the efficacy of four different protocols used for this purpose in Ahvaz.</p></sec><sec id="st3"><title>Material and methods</title><p>A total number of 400 patients with <italic>H. pylori</italic> infection were randomly divided into four groups (100 in each): (1) OAC: omeprazole (20 mg/b.i.d.), amoxicillin (1000 mg/b.i.d.), clarithromycin (500 mg/b.i.d.) for 10 days. (2) OCF: omeprazole (20 mg/b.i.d.), ciprofloxacin (500 mg/b.i.d.), furazolidone (100 mg/b.i.d.) for 10 days. (3) OBAM: omeprazole (20 mg/b.i.d.), bismuth subcitrate (240 mg/b.i.d.), amoxicillin (1000 mg/b.i.d.), metronidazol (500 mg/b.i.d.) for 14 days. (4) OBTM: omeprazole (20 mg/b.i.d.), bismuth subcitrate (240 mg/b.i.d.), tetracycline (500 mg/b.i.d.), metronidazol (500 mg/b.i.d.) for 14 days. At the end the viability of the bacterium was assessed by C<sup>14</sup> urea breath test.</p></sec><sec id="st4"><title>Results</title><p>The rate of <italic>H. pylori</italic> eradication was 92%, 59%, 73%, and 76% in OAC, OCF, OBAM, and OBTM groups, respectively (based on intention to treat analysis). The eradication rate was 93.9%, 62.1%, 77.7%, and 84.4% in OAC, OCF, OBAM, and OBTM groups, respectively (based on per protocol analysis). There was a statistically significant increase in eradication rate in the OAC group in comparison with the others (<italic>p</italic> &#x0003c; 0.001).</p></sec><sec id="st5"><title>Conclusions</title><p>Standard triple therapy (omeprazole, amoxicillin, clarithromycin) remains the most effective regimen for <italic>H. pylori</italic> eradication in Ahvaz.</p></sec></abstract><kwd-group><kwd><italic>Helicobacter pylori</italic></kwd><kwd>Ahvaz</kwd><kwd>clarithromycin</kwd><kwd>bismuth subcitrate</kwd><kwd>metronidazol</kwd><kwd>ciprofloxacin</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="S0001"><title>Introduction</title><p>
<italic>Helicobacter pylori</italic> (<italic>H. pylori</italic>) was introduced to scientific society in the 1980s by Marshal and Warren, when they announced that the bacterium can be a cause for active chronic gastritis and peptic ulcer disease [<xref rid="CIT0001" ref-type="bibr">1</xref>]. Since that time research was started on the subject and to date it has shown that the microorganism can cause several diseases involving the gastrointestinal tract, including acute and chronic gastritis, atrophic gastritis, peptic ulcer disease, gastric mucosa-associated lymphoid tissue (MALT) lymphoma, and gastric adenocarcinoma [<xref rid="CIT0002" ref-type="bibr">2</xref>]. Among extraintestinal diseases, the bacillus has been correlated t\ura [<xref rid="CIT0003" ref-type="bibr">3</xref>], unexplained iron-deficiency anaemia [<xref rid="CIT0004" ref-type="bibr">4</xref>, <xref rid="CIT0005" ref-type="bibr">5</xref>], and idiopathic thrombocytopenic purpura (ITP) [<xref rid="CIT0006" ref-type="bibr">6</xref>], and its eradication has been recommended in these cases. The eradication of <italic>H. pylori</italic> is also associated with decreasing the rate of gastrointestinal bleeding in users of nonsteroidal anti-inflammatory drugs (NSAIDs) [<xref rid="CIT0007" ref-type="bibr">7</xref>]. Therefore, eradication of the infection can result in different levels of decreasing morbidity and mortality generally. It is documented that successful eradication of the bacterium can make the patient medication free, even in complicated peptic ulcer cases [<xref rid="CIT0008" ref-type="bibr">8</xref>].</p><p>Various guidelines for the management of <italic>H. pylori</italic> infection are available worldwide. Among these, the latest one is the &#x0201c;Maastricht IV/ Florence Consensus Report&#x0201d; (2012), which was written by the European Helicobacter Study Group and suggests various treatment regimens, including: standard triple therapy (STT) with proton pump inhibitor (PPI)-clarithromycin and amoxicillin or metronidazole, bismuth-containing quadruple therapy, levofloxacin-containing triple therapy, and non-bismuth quadruple treatment (sequential (SQT) or concomitant). Sequential quadruple treatment includes a 5-day period with PPI-amoxicillin, followed by a 5-day period with PPI-clarithromycin-metronidazole (or tinidazole), and finally, treatments based on antimicrobial susceptibility testing [<xref rid="CIT0009" ref-type="bibr">9</xref>].</p><p>Because no new drug has been developed for this infection, a number of research projects have been carried out in recent years using different combinations of known antibiotics.</p></sec><sec id="S0002"><title>Aim</title><p>In this study we aimed to compare the efficacy of four protocols for <italic>H. pylori</italic> infection eradication: (1) omeprazole, amoxicillin, clarithromycin (OAC), (2) omeprazole, ciprofloxacin, furazolidone (OCF), (3) omeprazole, bismuth subcitrate, amoxicillin, metronidazol (OBAM), (4) omeprazole, bismuth subcitrate, tetracycline, and metronidazol (OBTM) in Ahvaz, southwest Iran.</p></sec><sec sec-type="material|methods" id="S0003"><title>Material and methods</title><sec id="S20004"><title>Subjects</title><p>This randomised clinical trial was carried out on 400 patients with peptic complications, who referred to governmental gastroenterology clinics of Ahvaz (south-west of Iran) between January and September 2010. Simple random selection of patients was carried out on group stratification based on age and sex. All patients were candidates for upper gastrointestinal (GI) endoscopy. The <italic>H. pylori</italic> infection was proven by a positive rapid urease test (RUT, 72.1% of patients) or a positive histopathological examination (27.9% of patients) of the biopsy specimens obtained from stomach antrum and corpus.</p><p>The exclusion criteria included: a history of G6PD deficiency, previous gastric surgery, drug allergies, chronic hepatic, renal and pulmonary disease, gastrointestinal malignancies, taking drugs such as antibiotics, gastric acid inhibitors, NSAIDs during the last month, pregnancy, and breast feeding.</p><p>The study was approved by the ethical committee of the Ahvaz Jundishapour University of Medical Sciences. All volunteers signed an informed written consent form before entering the study.</p></sec><sec id="S20005"><title>Study design</title><p>Each 100 consecutive patients were enrolled to receive one of the four different protocols described below: (1) OAC group: omeprazole (20 mg/b.i.d.), amoxicillin (1000 mg/b.i.d.), clarithromycin (500 mg/b.i.d.) for 10 days. (2) OCF group: omeprazole (20 mg/b.i.d.), ciprofloxacin (500 mg/b.i.d.), furazolidone (100 mg/b.i.d.) for 10 days. (3) OBAM group: omeprazole (20 mg/b.i.d.), bismuth subcitrate (240 mg/b.i.d.), amoxicillin (1000 mg/b.i.d.), metronidazol (500 mg/b.i.d.) for 14 days. (4) OBTM group: omeprazole (20 mg/b.i.d.), bismuth subcitrate (240 mg/b.i.d.), tetracycline (500 mg/b.i.d.), metronidazol (500 mg/b.i.d.) for 14 days.</p><p>After accomplishing the intervention period, the patients&#x02019; compliance and appearance of side effects were assessed via an interview.</p><p>The patient's compliance was categorized as follows: good (taking 80% of the drugs in the regimen), fair (taking 60&#x02013;80% of the drugs), and poor (taking less than 60% of the drugs). Patients with poor compliance were omitted from the study.</p><p>In terms of presenting side effects, the patients were categorised as follows: mild (no interference with daily activities), moderate (mild interference with daily activities), and severe (completely stopped daily activities).</p><p>All patients made an appointment for C<sup>14</sup> urea breath test (C<sup>14</sup>UBT) 8 weeks after the end of study in order to avoid false negative findings [<xref rid="CIT0010" ref-type="bibr">10</xref>]. Patients were advised to stop using any antibiotics, gastric acid inhibitors, or bismuth subcitrate 2 weeks prior to the test.</p></sec><sec id="S20006"><title>Assessment of Helicobacter pylori status</title><p>Biopsy specimens were taken during upper gastrointestinal endoscopy either for rapid urease test (CLO test, Campylobacter-like organism test) (Ballard Medical Products, Draper, UT, USA) or for histological assessment. In the latter case, the specimens were fixed in 10% formalin and stained with haematoxylin-eosin and Giemsa stain.</p><p>C<sup>14</sup>UBT was used to evaluate the <italic>H. pylori</italic> viability at the end of study. Patients who did not take the test were excluded from the study. The test was based upon the ability of <italic>H. pylori</italic> to convert urea to ammonia and carbon dioxide [<xref rid="CIT0011" ref-type="bibr">11</xref>].</p><p>The test was done 30 min after oral administration of the capsules containing C<sup>14</sup> urea (37 kBq). Patients exhaled in KOH solution until it became colourless, which was the sign that 1 mmol of CO<sub>2</sub> had been trapped. After adding 15 ml of scintillation fluid, the radioactivity in the collected samples was measured by liquid scintillation counter (LKB Wallac &#x02013; Rack Beta Spectral) [<xref rid="CIT0012" ref-type="bibr">12</xref>].</p><p>The test was considered as negative if the amount of CO<sub>2</sub> was less than 50, and a negative test was considered a successful treatment.</p></sec><sec id="S20007"><title>Statistical analysis</title><p>Data were analysed using &#x003c7;<sup>2</sup> statistical test. Value of <italic>p</italic> &#x0003c; 0.05 was considered as significant.</p></sec></sec><sec sec-type="results" id="S0008"><title>Results</title><sec id="S20009"><title>Demographic data</title><p>A total of 400 patients (211 males, 189 females) were recruited (<xref ref-type="table" rid="T0001">Table I</xref>). Each consecutive 100 patients were randomly entered to one of the groups: OAC, OCF, OBAM, and OBTM. Twenty-three patients (2, 5, 6, and 10 patients from the OAC, OCF, OBAM, and OBTM groups, respectively) were totally excluded from the per protocol analysis. The reasons for exclusion were side effects occurrence (1, 3, 2, and 5 cases from the OAC, OCF, OBAM, and OBTM groups, respectively) and missing the follow-up program (1, 2, 4, and 5 cases from the OAC, OCF, OBAM, and OBTM groups, respectively). None of the patients had poor compliance. At the end of the study, a total of 377 patients were analysed in per protocol analysis (<xref ref-type="fig" rid="F0001">Figure 1</xref>). The most common chief complaints for being referred to the gastrointestinal clinic and undergoing an upper GI endoscopy were epigastric pain and dyspepsia/heartburn in decreasing order of frequency in all treatment groups. Flatulence and strong family history of gastric cancer were the other common symptoms. The most common endoscopic findings were gastritis, and normal and duodenal ulcer, in all treatment groups, but the OBTM group, which showed gastritis, erosive gastritis, and duodenal ulcer as common endoscopic features. The side-effect profile in the different groups is shown in <xref ref-type="table" rid="T0002">Table II</xref>. The most common side effects in the OAC, OCF, OBAM, and OBTM groups were dizziness/taste perversion, nausea/vomiting, dizziness, and taste perversion, respectively. There was no complaint of abdominal pain, constipation, and skin rashes in any of the groups.
</p><fig id="F0001" position="float"><label>Figure 1</label><caption><p>Study design</p></caption><graphic xlink:href="PG-10-24567-g001"/></fig><table-wrap id="T0001" position="float"><label>Table I</label><caption><p>Demographic characteristics of volunteers</p></caption><table frame="void" rules="rows" width="100%"><thead><tr><th align="left" rowspan="1" colspan="1">Parameter</th><th align="center" rowspan="1" colspan="1">OAC</th><th align="center" rowspan="1" colspan="1">OCF</th><th align="center" rowspan="1" colspan="1">OBAM</th><th align="center" rowspan="1" colspan="1">OBTM</th><th align="center" rowspan="1" colspan="1">Total</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Total number (ITT<xref ref-type="table-fn" rid="TF0001">*</xref>)</td><td align="center" rowspan="1" colspan="1">100</td><td align="center" rowspan="1" colspan="1">100</td><td align="center" rowspan="1" colspan="1">100</td><td align="center" rowspan="1" colspan="1">100</td><td align="center" rowspan="1" colspan="1">400</td></tr><tr><td align="left" rowspan="1" colspan="1">Included per-protocol (PP)</td><td align="center" rowspan="1" colspan="1">98</td><td align="center" rowspan="1" colspan="1">95</td><td align="center" rowspan="1" colspan="1">94</td><td align="center" rowspan="1" colspan="1">90</td><td align="center" rowspan="1" colspan="1">377</td></tr><tr><td align="left" rowspan="1" colspan="1">Female, <italic>n</italic> (%)</td><td align="center" rowspan="1" colspan="1">43 (43.9)</td><td align="center" rowspan="1" colspan="1">50 (52.6)</td><td align="center" rowspan="1" colspan="1">43 (45.7)</td><td align="center" rowspan="1" colspan="1">43 (47.8)</td><td align="center" rowspan="1" colspan="1">179 (47.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">Male, <italic>n</italic> (%)</td><td align="center" rowspan="1" colspan="1">55 (56.1)</td><td align="center" rowspan="1" colspan="1">45 (47.4)</td><td align="center" rowspan="1" colspan="1">51 (54.3)</td><td align="center" rowspan="1" colspan="1">47 (52.2)</td><td align="center" rowspan="1" colspan="1">198 (52.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">Age range (mean &#x000b1; SD) [years]</td><td align="center" rowspan="1" colspan="1">10&#x02013;70 (40 &#x000b1;13.1)</td><td align="center" rowspan="1" colspan="1">14&#x02013;80 (41 &#x000b1;13.18)</td><td align="center" rowspan="1" colspan="1">16&#x02013;73 (38 &#x000b1;11.79)</td><td align="center" rowspan="1" colspan="1">15&#x02013;79 (39 &#x000b1;12.53)</td><td align="left" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="TF0001"><label>*</label><p>Intention to treat. There was no significant difference between the groups regarding sex and age distribution (p = 0.65%).</p></fn></table-wrap-foot></table-wrap><table-wrap id="T0002" position="float"><label>Table II</label><caption><p>Adverse effects</p></caption><table frame="void" rules="rows" width="100%"><thead><tr><th align="left" rowspan="1" colspan="1">Side effect</th><th align="center" rowspan="1" colspan="1">OAC, <italic>n</italic> (%)</th><th align="center" rowspan="1" colspan="1">OCF, <italic>n</italic> (%)</th><th align="center" rowspan="1" colspan="1">OBAM, <italic>n</italic> (%)</th><th align="center" rowspan="1" colspan="1">OBTM, <italic>n</italic> (%)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Abdominal pain</td><td align="center" rowspan="1" colspan="1">&#x02013;</td><td align="center" rowspan="1" colspan="1">&#x02013;</td><td align="center" rowspan="1" colspan="1">&#x02013;</td><td align="center" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td align="left" rowspan="1" colspan="1">Constipation</td><td align="center" rowspan="1" colspan="1">&#x02013;</td><td align="center" rowspan="1" colspan="1">&#x02013;</td><td align="center" rowspan="1" colspan="1">&#x02013;</td><td align="center" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td align="left" rowspan="1" colspan="1">Diarrhoea</td><td align="center" rowspan="1" colspan="1">5 (5.1)</td><td align="center" rowspan="1" colspan="1">1 (1.05)</td><td align="center" rowspan="1" colspan="1">2 (2.12)</td><td align="center" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td align="left" rowspan="1" colspan="1">Dizziness</td><td align="center" rowspan="1" colspan="1">10 (10.2)</td><td align="center" rowspan="1" colspan="1">1 (1.05)</td><td align="center" rowspan="1" colspan="1">7 (7.44)</td><td align="center" rowspan="1" colspan="1">2 (2.22)</td></tr><tr><td align="left" rowspan="1" colspan="1">Taste perversion</td><td align="center" rowspan="1" colspan="1">10 (10.2)</td><td align="center" rowspan="1" colspan="1">&#x02013;</td><td align="center" rowspan="1" colspan="1">5 (5.31)</td><td align="center" rowspan="1" colspan="1">6 (6.66)</td></tr><tr><td align="left" rowspan="1" colspan="1">Headache</td><td align="center" rowspan="1" colspan="1">3 (3.06)</td><td align="center" rowspan="1" colspan="1">2 (2.1)</td><td align="center" rowspan="1" colspan="1">4 (4.25)</td><td align="center" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td align="left" rowspan="1" colspan="1">Anorexia</td><td align="center" rowspan="1" colspan="1">3 (3.06)</td><td align="center" rowspan="1" colspan="1">5 (5.26)</td><td align="center" rowspan="1" colspan="1">4 (4.255)</td><td align="center" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td align="left" rowspan="1" colspan="1">Nausea/vomiting</td><td align="center" rowspan="1" colspan="1">4 (4.08)</td><td align="center" rowspan="1" colspan="1">12 (12.63)</td><td align="center" rowspan="1" colspan="1">2 (2.12)</td><td align="center" rowspan="1" colspan="1">2 (2.12)</td></tr><tr><td align="left" rowspan="1" colspan="1">Skin rash</td><td align="center" rowspan="1" colspan="1">&#x02013;</td><td align="center" rowspan="1" colspan="1">&#x02013;</td><td align="center" rowspan="1" colspan="1">&#x02013;</td><td align="center" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td align="left" rowspan="1" colspan="1">Others</td><td align="center" rowspan="1" colspan="1">1 (1.02)</td><td align="center" rowspan="1" colspan="1">&#x02013;</td><td align="center" rowspan="1" colspan="1">&#x02013;</td><td align="center" rowspan="1" colspan="1">1 (1.11)</td></tr><tr><td align="left" rowspan="1" colspan="1">Total</td><td align="center" rowspan="1" colspan="1">36 (36.73)</td><td align="center" rowspan="1" colspan="1">21 (22.1)</td><td align="center" rowspan="1" colspan="1">22 (23.4)</td><td align="center" rowspan="1" colspan="1">9 (10)</td></tr></tbody></table></table-wrap></sec><sec id="S20010"><title>C<sup>14</sup> urea breath test</title><p>The rate of <italic>H. pylori</italic> eradication (negative result of C<sup>14</sup>UBT) based on intention to treat analysis (ITT) was 92%, 59%, 73%, and 76% in the OAC, OCF, OBAM, and OBTM groups, respectively. Eradication rate based on per protocol (PP) analysis was 93.9%, 62.1%, 77.7%, and 84.4% in the OAC, OCF, OBAM, and OBTM groups, respectively (<xref ref-type="fig" rid="F0002">Figure 2</xref>). There was a statistically significant increase in eradication rate in the OAC group compared to the other ones (<italic>p</italic> &#x0003c; 0.001).</p><fig id="F0002" position="float"><label>Figure 2</label><caption><p>Eradication rate of <italic>H. pylori</italic> in four different groups based on per protocol analysis (%)</p><p>*Value of p &#x0003c; 0.05 indicates significant difference versus OCF, OBAM and OBTM. OAC &#x02013; omeprazole, amoxicillin, clarithromycin; OCF &#x02013; omeprazole, ciprofloxacin, furazolidone; OBAM &#x02013; omeprazole, bismuth subcitrate, amoxicillin, metronidazole; OBTM &#x02013; omeprazole, bismuth subcitrate, tetracycline, and metronidazole.</p></caption><graphic xlink:href="PG-10-24567-g002"/></fig></sec></sec><sec sec-type="discussion" id="S0011"><title>Discussion</title><p>In this study the eradication rates of <italic>H. pylori</italic> in patients with a documented infection were compared using four different regimens: OAC: omeprazole, amoxicillin, clarithromycin; OCF: omeprazole, ciprofloxacin, furazolidone; OBAM: omeprazole, bismuth subcitrate, amoxicillin, metronidazol; and OBTM: omeprazole, bismuth subcitrate, tetracycline, metronidazol. The rates of eradication achieved in this study were acceptable apart from the OCF regimen, according to a pooled-data analysis on this issue, which showed that a rate of &#x0003e; 75% eradication is an acceptable rate [<xref rid="CIT0013" ref-type="bibr">13</xref>].</p><p>In the current study we showed that the eradication was more effective with standard triple therapy (STT, a PPI-clarithromycin and amoxicillin) regimen in comparison to the other three regimens. Standard triple therapy remains the first line treatment for eradication of <italic>H. pylori</italic> around the world, unless the area in question has a resistance rate above 15&#x02013;20% [<xref rid="CIT0009" ref-type="bibr">9</xref>]. However, Shiota and Yamaoka recently reported that quadruple therapy should be replaced by clarithromycin-based triple therapy as initial therapy for eradication of this bacterium [<xref rid="CIT0014" ref-type="bibr">14</xref>].</p><p>The sole study on <italic>H. pylori</italic> resistance rate in Ahwaz showed that the rate of clarithromycin resistance in this city is 24%, which places the city in the category of regions with high resistance to clarithromycin [<xref rid="CIT0015" ref-type="bibr">15</xref>]. Also Mohammadi <italic>et al</italic>. in 2003 already warned that a near 20% rate of clarithromycin resistance should alert to the frequency of macrolide resistant strains in Iran [<xref rid="CIT0016" ref-type="bibr">16</xref>]. According to the evidence mentioned above, the STT should not be used as a treatment regimen for <italic>H. pylori</italic> eradication in Ahvaz. But this regimen is still used, maybe due to the lack of any other report on this issue. Albeit, researche on the entity of clarithromycin resistance rate in areas of Iran do not show parallel results; some report that the rate of clarithromycin resistance is under the threshold mentioned earlier [<xref rid="CIT0017" ref-type="bibr">17</xref>, <xref rid="CIT0018" ref-type="bibr">18</xref>], and some report a rate of resistance exactly within the threshold range of 15&#x02013;20% or very close to it [<xref rid="CIT0019" ref-type="bibr">19</xref>&#x02013;<xref rid="CIT0021" ref-type="bibr">21</xref>]. The results of another study performed in Ahvaz in 2007 by Hajiani <italic>et al</italic>. also confirm our results in this respect, showing that the STT regimen is more powerful than a quadruple therapy in the eradication of this infection; this shows that the high rate of clarithromycin resistance in this region can be overcome by combination STT [<xref rid="CIT0022" ref-type="bibr">22</xref>]. The rate of eradication was 92% with the OAC regimen in our study, which is confirmed by at least four studies that reported an eradication rate of &#x0003e; 75% with this regimen [<xref rid="CIT0023" ref-type="bibr">23</xref>&#x02013;<xref rid="CIT0026" ref-type="bibr">26</xref>]. Also, our eradication rate was higher than all these studies, which may refer to the much lower percentage of excluded patients in per protocol analysis in our study (2%) as compared with 17&#x02013;23% in the above-mentioned literature.</p><p>In addition, two of these studies used a shorter treatment duration (7 days) than the current study (10 days) [<xref rid="CIT0025" ref-type="bibr">25</xref>, <xref rid="CIT0026" ref-type="bibr">26</xref>].</p><p>There is no report of resistance of <italic>H. pylori</italic> strains to furazolidone and ciprofloxacin in Ahvaz. A study from the north of Iran in 2011 reported the rate of resistance was 34.5% and 61.4% for ciprofloxacin and furazolidone, respectively [<xref rid="CIT0027" ref-type="bibr">27</xref>]. Another study from a big referral medical centre for paediatrics in Tehran showed a rate of 34.5% resistance to ciprofloxacin, but it has no data on furazolidone [<xref rid="CIT0028" ref-type="bibr">28</xref>]. The results of the latter study can be generalized to Ahvaz, because the place where the study was performed is a big referral centre in Iran, and this may explain why the OCF regimen has a much lower eradication rate compared with the other regimens.</p><p>The rate of eradication with the OBTM regimen in our study was 76%, which is higher than the reports by Mantzaris <italic>et al</italic>. and Gomollon <italic>et al</italic>. The reason could be due to the shorter treatment period (7 and 10 days vs. 14 days in the present study), the smaller sample size (48 and 71 patients vs. 100 patients in the present study), and the higher percentage of excluded patients in per protocol analysis (31.25% and 35% vs. 10% in the current study) [<xref rid="CIT0023" ref-type="bibr">23</xref>, <xref rid="CIT0025" ref-type="bibr">25</xref>].</p><p>However, the eradication rate in our study with the OBTM regimen was lower than that seen in the study by Laine <italic>et al</italic>. and Malfertheiner <italic>et al</italic>., which may be due to lower sample size (100 patients in our study vs. 138 and 218 patients, respectively) and lower doses of tetracycline, metronidazole, and bismuth subcitrate [<xref rid="CIT0024" ref-type="bibr">24</xref>, <xref rid="CIT0029" ref-type="bibr">29</xref>].</p><p>Another point in this study was that the more powerful regimen (OAC) had the higher percentage of total side effect occurrence. The reason can be the fact that the severity of side effects in the OAC group is very low, as only 1 patient in this group (fewer in number in comparison to other groups) left the study because of side effect appearance.</p></sec><sec sec-type="conclusions" id="S0012"><title>Conclusions</title><p>We have shown that despite heterogeneous reports about the resistance of <italic>H. pylori</italic> strains to clarithromycin in Iran and the record of a high rate of resistance to clarithromycin in Ahvaz, standard triple therapy (omeprazole, amoxicillin, clarithromycin) remains the most effective regimen for eradicating of <italic>H. pylori</italic> infection in Ahvaz.</p></sec></body><back><ack><title>Acknowledgments</title><p>The authors would like to thank Ahvaz Jundishpur University of Medical Sciences for providing financial support.</p></ack><sec id="S0013"><title>Conflict of interest</title><p>The authors declare no conflict of interest.</p></sec><ref-list><title>References</title><ref id="CIT0001"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marshall</surname><given-names>B</given-names></name><name><surname>Warren</surname><given-names>JR</given-names></name></person-group><article-title>Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration</article-title><source>Lancet</source><year>1984</year><volume>323</volume><fpage>1311</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">6145023</pub-id></element-citation></ref><ref id="CIT0002"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roesler</surname><given-names>BM</given-names></name><name><surname>Costa</surname><given-names>SC</given-names></name><name><surname>Zeitune</surname><given-names>JM</given-names></name></person-group><article-title>Eradication treatment of Helicobacter pylori infection: its importance and possible relationship in preventing the development of gastric cancer</article-title><source>ISRN Gastroenterology</source><year>2012</year><volume>2012</volume><fpage>935410</fpage><pub-id pub-id-type="pmid">22778979</pub-id></element-citation></ref><ref id="CIT0003"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ulas</surname><given-names>T</given-names></name><name><surname>Tursun</surname><given-names>I</given-names></name><name><surname>Dal</surname><given-names>MS</given-names></name><etal/></person-group><article-title>Rapid improvement of Henoch-Schonlein purpura associated with the treatment of Helicobacter pylori infection</article-title><source>J Res Med Sci</source><year>2012</year><volume>17</volume><fpage>1086</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">23833587</pub-id></element-citation></ref><ref id="CIT0004"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qu</surname><given-names>XH</given-names></name><name><surname>Huang</surname><given-names>XL</given-names></name><name><surname>Xiong</surname><given-names>P</given-names></name><etal/></person-group><article-title>Does Helicobacter pylori infection play a role in iron deficiency anemia? A meta-analysis</article-title><source>World J Gastroenterol</source><year>2010</year><volume>16</volume><fpage>886</fpage><lpage>96</lpage><pub-id pub-id-type="pmid">20143469</pub-id></element-citation></ref><ref id="CIT0005"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muhsen</surname><given-names>K</given-names></name><name><surname>Cohen</surname><given-names>D</given-names></name></person-group><article-title>Helicobacter pylori infection and iron stores: a systematic review and meta-analysis</article-title><source>Helicobacter</source><year>2008</year><volume>13</volume><fpage>323</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">19250507</pub-id></element-citation></ref><ref id="CIT0006"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arnold</surname><given-names>DM</given-names></name><name><surname>Bernotas</surname><given-names>A</given-names></name><name><surname>Nazi</surname><given-names>I</given-names></name><etal/></person-group><article-title>Platelet count response to H. pylori treatment in patients with immune thrombocytopenic purpura with and without H. pylori infection: a systematic review</article-title><source>Haematologica</source><year>2009</year><volume>94</volume><fpage>850</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">19483158</pub-id></element-citation></ref><ref id="CIT0007"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roug</surname><given-names>S</given-names></name><name><surname>Madsen</surname><given-names>LG</given-names></name></person-group><article-title>Importance of post-treatment follow-up to secure sufficient eradication therapy for Helicobacter pylori</article-title><source>Dan Med J</source><year>2012</year><volume>59</volume><fpage>A4553</fpage><pub-id pub-id-type="pmid">23290289</pub-id></element-citation></ref><ref id="CIT0008"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gisbert</surname><given-names>JP</given-names></name><name><surname>Calvet</surname><given-names>X</given-names></name><name><surname>Cosme</surname><given-names>A</given-names></name><etal/></person-group><article-title>Long-term follow-up of 1,000 patients cured of Helicobacter pylori infection following an episode of peptic ulcer bleeding</article-title><source>Am J Gastroenterol</source><year>2012</year><volume>107</volume><fpage>1197</fpage><lpage>204</lpage><pub-id pub-id-type="pmid">22613904</pub-id></element-citation></ref><ref id="CIT0009"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malfertheiner</surname><given-names>P</given-names></name><name><surname>Megraud</surname><given-names>F</given-names></name><name><surname>O'Morain</surname><given-names>CA</given-names></name><etal/></person-group><article-title>Management of Helicobacter pylori infection: the Maastricht IV/Florence Consensus Report</article-title><source>Gut</source><year>2012</year><volume>61</volume><fpage>646</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">22491499</pub-id></element-citation></ref><ref id="CIT0010"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bravo</surname><given-names>LE</given-names></name><name><surname>Realpe</surname><given-names>JL</given-names></name><name><surname>Campo</surname><given-names>C</given-names></name><etal/></person-group><article-title>Effects of acid suppression and bismuth medications on the performance of diagnostic tests for Helicobacter pylori infection</article-title><source>Am J Gastroenterol</source><year>1999</year><volume>94</volume><fpage>2380</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">10483995</pub-id></element-citation></ref><ref id="CIT0011"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chey</surname><given-names>WD</given-names></name><name><surname>Wong</surname><given-names>BC</given-names></name></person-group><article-title>American College of Gastroenterology guideline on the management of Helicobacter pylori infection</article-title><source>Am J Gastroenterol</source><year>2007</year><volume>102</volume><fpage>1808</fpage><lpage>25</lpage><pub-id pub-id-type="pmid">17608775</pub-id></element-citation></ref><ref id="CIT0012"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Artiko</surname><given-names>VM</given-names></name><name><surname>Obradovic</surname><given-names>V</given-names></name><name><surname>Petrovic</surname><given-names>N</given-names></name><etal/></person-group><article-title>14C-urea breath test in the detection of Helicobacter pylori infection</article-title><source>Nucl Med Rev Cent East Eur</source><year>2001</year><volume>4</volume><fpage>101</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">14600894</pub-id></element-citation></ref><ref id="CIT0013"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zullo</surname><given-names>A</given-names></name><name><surname>De Francesco</surname><given-names>V</given-names></name><name><surname>Hassan</surname><given-names>C</given-names></name><etal/></person-group><article-title>The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis</article-title><source>Gut</source><year>2007</year><volume>56</volume><fpage>1353</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">17566020</pub-id></element-citation></ref><ref id="CIT0014"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shiota</surname><given-names>S</given-names></name><name><surname>Yamaoka</surname><given-names>Y</given-names></name></person-group><article-title>Strategy for the treatment of Helicobacter pylori infection</article-title><source>Curr Pharm Des</source><year>2014</year><volume>20</volume><fpage>4489</fpage><lpage>500</lpage><pub-id pub-id-type="pmid">24180402</pub-id></element-citation></ref><ref id="CIT0015"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moosavian</surname><given-names>M</given-names></name><name><surname>Tajbakhsh</surname><given-names>S</given-names></name><name><surname>Samarbaf-Zadeh</surname><given-names>AR</given-names></name></person-group><article-title>Rapid detection of clarithromycin-resistant Helicobacter pylori in patients with dyspepsia by fluorescent in situ hybridization (FISH) compared with the E-test</article-title><source>Ann Saudi Med</source><year>2006</year><volume>27</volume><fpage>84</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">17356313</pub-id></element-citation></ref><ref id="CIT0016"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mohammadi</surname><given-names>M</given-names></name><name><surname>Doroud</surname><given-names>D</given-names></name><name><surname>Massarrat</surname><given-names>S</given-names></name><etal/></person-group><article-title>Clarithromycin resistance in Iranian H. pylori strains before introduction of clarithromycin</article-title><source>Helicobacter</source><year>2003</year><volume>8</volume><fpage>80</fpage><pub-id pub-id-type="pmid">12603622</pub-id></element-citation></ref><ref id="CIT0017"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kohanteb</surname><given-names>J</given-names></name><name><surname>Bazargani</surname><given-names>A</given-names></name><name><surname>Saberi-Firoozi</surname><given-names>M</given-names></name><etal/></person-group><article-title>Antimicrobial susceptibility testing of Helicobacter pylori to selected agents by agar dilution method in Shiraz-Iran</article-title><source>Indian J Med Microbiol</source><year>2007</year><volume>25</volume><fpage>374</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">18087088</pub-id></element-citation></ref><ref id="CIT0018"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siavashi</surname><given-names>F</given-names></name><name><surname>Safari</surname><given-names>F</given-names></name><name><surname>Doratotaj</surname><given-names>D</given-names></name><etal/></person-group><article-title>Antimicrobial resistance of Helicobacter pylori isolates from Iranian adults and children</article-title><source>Arch Iran Med</source><year>2006</year><volume>9</volume><fpage>308</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">17061600</pub-id></element-citation></ref><ref id="CIT0019"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mirzaei</surname><given-names>N</given-names></name><name><surname>Poursina</surname><given-names>F</given-names></name><name><surname>Faghri</surname><given-names>J</given-names></name><etal/></person-group><article-title>Prevalence of resistance to Helicobacter pylori strains to selected antibiotics in Isfahan, Iran</article-title><source>Jundishapur J Microbiol</source><year>2013</year><volume>6</volume><fpage>e6342</fpage></element-citation></ref><ref id="CIT0020"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khademi</surname><given-names>F</given-names></name><name><surname>Faghri</surname><given-names>J</given-names></name><name><surname>Poursina</surname><given-names>F</given-names></name><etal/></person-group><article-title>Resistance pattern of Helicobacter pylori strains to clarithromycin, metronidazole, and amoxicillin in Isfahan, Iran</article-title><source>J Res Med Sci</source><year>2013</year><volume>18</volume><fpage>1056</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">24523796</pub-id></element-citation></ref><ref id="CIT0021"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mohammadi</surname><given-names>M</given-names></name><name><surname>Doroud</surname><given-names>D</given-names></name><name><surname>Mohajerani</surname><given-names>N</given-names></name><etal/></person-group><article-title>Helicobacter pylori antibiotic resistance in Iran</article-title><source>World J Gastroenterol</source><year>2005</year><volume>11</volume><fpage>6009</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">16273615</pub-id></element-citation></ref><ref id="CIT0022"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hajiani</surname><given-names>E</given-names></name><name><surname>Hashemi</surname><given-names>J</given-names></name><name><surname>Vosoghi</surname><given-names>T</given-names></name></person-group><article-title>Comparison of a 10 day triple and a two-week quadruple therapy in eradicating Helicobacter pylori infection in patients referred to Imam Khomeini Hospital Clinics Ahwaz, Iran</article-title><source>Jundishapur Journal of Natural Pharmaceutical Products</source><year>2007</year><volume>3</volume><fpage>45</fpage><lpage>52</lpage></element-citation></ref><ref id="CIT0023"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mantzaris</surname><given-names>GJ</given-names></name><name><surname>Petraki</surname><given-names>K</given-names></name><name><surname>Archavlis</surname><given-names>E</given-names></name><etal/></person-group><article-title>Omeprazole triple therapy versus omeprazole quadruple therapy for healing duodenal ulcer and eradication of Helicobacter pylori infection: a 24-month follow-up study</article-title><source>Eur J Gastroenterol Hepatol</source><year>2002</year><volume>14</volume><fpage>1237</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">12439119</pub-id></element-citation></ref><ref id="CIT0024"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laine</surname><given-names>L</given-names></name><name><surname>Hunt</surname><given-names>R</given-names></name><name><surname>El-Zimaity</surname><given-names>H</given-names></name><etal/></person-group><article-title>Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial</article-title><source>Am J Gastroenterol</source><year>2003</year><volume>98</volume><fpage>562</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">12650788</pub-id></element-citation></ref><ref id="CIT0025"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gomoll&#x000f3;n</surname><given-names>F</given-names></name><name><surname>Valdep&#x000e9;rez</surname><given-names>J</given-names></name><name><surname>Garuz</surname><given-names>R</given-names></name><etal/></person-group><article-title>Cost-effectiveness analysis of 2 strategies of Helicobacter pylori eradication: results of a prospective and randomized study in primary care [Spain]</article-title><source>Med Clin</source><year>2000</year><volume>115</volume><fpage>1</fpage><lpage>6</lpage></element-citation></ref><ref id="CIT0026"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calvet</surname><given-names>X</given-names></name><name><surname>Ducons</surname><given-names>J</given-names></name><name><surname>Guardiola</surname><given-names>J</given-names></name><etal/></person-group><article-title>One-week triple vs. quadruple therapy for Helicobacter pylori infection &#x02013; a randomized trial</article-title><source>Aliment Pharmacol Ther</source><year>2002</year><volume>16</volume><fpage>1261</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">12144575</pub-id></element-citation></ref><ref id="CIT0027"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abadi</surname><given-names>ATB</given-names></name><name><surname>Taghvaei</surname><given-names>T</given-names></name><name><surname>Mobarez</surname><given-names>AM</given-names></name><etal/></person-group><article-title>Frequency of antibiotic resistance in Helicobacter pylori strains isolated from the northern population of Iran</article-title><source>J Microbiol</source><year>2011</year><volume>49</volume><fpage>987</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">22203563</pub-id></element-citation></ref><ref id="CIT0028"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Falsafi</surname><given-names>T</given-names></name><name><surname>Mobasheri</surname><given-names>F</given-names></name><name><surname>Nariman</surname><given-names>F</given-names></name><etal/></person-group><article-title>Susceptibilities to different antibiotics of Helicobacter pylori strains isolated from patients at the pediatric medical center of Tehran, Iran</article-title><source>J Clin Microbiol</source><year>2004</year><volume>42</volume><fpage>387</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">14715786</pub-id></element-citation></ref><ref id="CIT0029"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malfertheiner</surname><given-names>P</given-names></name><name><surname>Bazzoli</surname><given-names>F</given-names></name><name><surname>Delchier</surname><given-names>JC</given-names></name><etal/></person-group><article-title>Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial</article-title><source>Lancet</source><year>2011</year><volume>377</volume><fpage>905</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">21345487</pub-id></element-citation></ref></ref-list></back></article>